# Louisiana Lawmakers Pass Bill To Create Psychedelic Therapy Pilot Program > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/louisiana-psychedelic-therapy-pilot-program/ > **Published:** 2026-06-01T10:31:36-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:53:48-04:00 > **Clinical Summary:** Louisiana's psychedelic therapy pilot program advances clinical research into psilocybin, MDMA, and ibogaine for treatment-resistant conditions. --- ✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyResearchMental HealthNeurologyAnxietySafetyIndustry Why This Matters Clinicians should be aware that Louisiana’s psychedelic therapy pilot program legitimizes [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) into psilocybin, ibogaine, and MDMA as potential treatments for conditions where conventional therapies have failed, potentially expanding their therapeutic toolkit in coming years. This regulatory shift signals that psychedelic-assisted therapy may transition from research-only status to clinical practice, requiring clinicians to understand these modalities’ mechanisms, safety profiles, and patient selection criteria to appropriately counsel patients about emerging options. Patients with treatment-resistant conditions like PTSD and depression should know that state-sanctioned trials are advancing evidence-based psychedelic therapies, creating pathways for access while clinical evidence continues to accumulate. Clinical Summary Louisiana’s passage of legislation establishing a psychedelic therapy pilot program represents a significant regulatory shift that may indirectly impact [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice by expanding the therapeutic landscape for patients with treatment-resistant conditions such as depression, PTSD, and addiction disorders. The bill authorizes controlled clinical trials investigating psilocybin, ibogaine, and MDMA, substances that operate through distinct [neurobiological mechanisms](https://cedclinic.com/cannabis-tolerance-behavioral-models/) compared to cannabinoids but may address similar patient populations seeking alternatives to conventional pharmacotherapy. While this legislation focuses on psychedelics rather than cannabis directly, it signals growing state-level acceptance of plant-derived and psychoactive compounds for mental health treatment, potentially creating a more permissive regulatory environment for [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) and clinical applications. Clinicians should recognize that patients may view psychedelic-assisted therapy and cannabis as part of a broader spectrum of [alternative treatments](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/), necessitating informed discussions about evidence, safety profiles, and potential drug interactions. The practical implication for clinicians is to stay informed about emerging psychedelic therapies in their jurisdiction, as these developments may influence patient expectations, research opportunities, and the regulatory trajectory of other plant-based medicines including cannabis. Dr. Caplan’s Take “We’re seeing the same regulatory logjam with psychedelics that we faced with cannabis for decades, and Louisiana’s pilot program is a pragmatic step that acknowledges what the neuroscience already shows: these compounds have legitimate therapeutic potential for treatment-resistant conditions. My patients with severe PTSD or end-stage depression deserve access to evidence-based options, and these programs create the legal framework we need to generate that evidence responsibly.” Clinical Perspective Louisiana’s psychedelic therapy pilot program represents an emerging policy shift that may eventually reshape treatment options for conditions like treatment-resistant depression and PTSD, though clinicians should recognize that these substances remain federally controlled and not yet approved for standard clinical use. While preclinical and early clinical data on psilocybin and MDMA-assisted therapy show promise, the evidence base remains limited and heterogeneous, with questions remaining about optimal dosing, patient selection criteria, and long-term safety in diverse populations. The pathway from state-level pilot programs to regulated clinical practice involves substantial regulatory and practical hurdles, and clinicians should be cautious about prematurely integrating these approaches into routine care or raising patient expectations beyond what current evidence supports. Simultaneously, the growing legal and research infrastructure around psychedelic-assisted therapy creates an opportunity for providers to stay informed about this evolving field and to identify patients who might qualify for legitimate clinical trials 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Louisiana%20Lawmakers%20Pass%20Bill%20To%20Create%20Psychedelic%20Therapy%20Pilot%20Program%20...%20-%20Marijuana%20Moment%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57038)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57038)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Louisiana%20Lawmakers%20Pass%20Bill%20To%20Create%20Psychedelic%20Therapy%20Pilot%20Program%20...%20-%20Marijuana%20Moment%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57038)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [CED Digest: 35 Items — April 09, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-april-2026-digest/) - [CED Digest: 30 Items — March 31, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 40 Items — March 24, 2026](https://cedclinic.com/cannabis-clinical-relevance-march-24-2026/) 📰 Source: [https://www.marijuanamoment.net/louisiana-lawmakers-pass-bill-to-create-psychedelic-therapy-pilot-program-funded-by-opioid-settlement-dollars-sending-it-to-governor/](https://www.marijuanamoment.net/louisiana-lawmakers-pass-bill-to-create-psychedelic-therapy-pilot-program-funded-by-opioid-settlement-dollars-sending-it-to-governor/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump Signs Order To Accelerate Legal Access To Psychedelics For Patients With Mental …](https://cedclinic.com/accelerate-psychedelic-assisted-therapies-mental-health-access/) Explore how federal initiatives are speeding up access to psychedelic therapies for mental health patients. [Read More](https://cedclinic.com/accelerate-psychedelic-assisted-therapies-mental-health-access/) [Connecticut Senate Votes To Expand Psychedelics Pilot Program In Anticipation Of FDA Approval](https://cedclinic.com/connecticut-psychedelics-pilot-program-expansion/) Learn about Connecticut’s efforts to broaden psychedelic therapy pilot programs ahead of FDA decisions. [Discover More](https://cedclinic.com/connecticut-psychedelics-pilot-program-expansion/) [Trump Administration ‘Very Anxious’ To Allow Psychedelic Therapy ‘As Quickly As Possible …](https://cedclinic.com/expedited-psychedelics-regulatory-review-2026/) Insights into federal administration’s stance on accelerating psychedelic therapy approvals. [Explore Article](https://cedclinic.com/expedited-psychedelics-regulatory-review-2026/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).